Hong Kong stock concept tracking|US will relax marijuana regulations, companies in the industry chain may usher in a turning point (with concept stocks)

The Zhitong Finance App learned that the US Department of Justice said on Thursday that it will immediately ease restrictions on some marijuana products and act quickly to reclassify marijuana as a less dangerous drug. This is one of the biggest changes in US drug policy in decades.

The move won't legalize marijuana across the US, but it is likely to reshape this $47 billion industry.

Although all but two states in the US have legalized marijuana in some form for medical use, and nearly half of the states have legalized marijuana for recreational use, the industry still faces many barriers at the federal level.

Medical marijuana products regulated by states are now moving from categories classified as highly addictive drugs, such as heroin, to less restricted categories, that is, products with low to moderate potential for abuse, including common pain relievers, ketamine, and testosterone.

Cannabis products approved by the US Food and Drug Administration will also fall into this category.

Hong Kong stocks involving the concept of US cannabis policy:

Jiayao Holdings (01626): An announcement was issued. The Group has continued to focus on health and biomedicine related fields in recent years. The Group officially launched cannabidiol (CBD) related business in April 2026. Currently, the Group is mainly engaged in the procurement and export business of CBD from China, and its products are mainly sold to skincare, cosmetic and pharmaceutical companies in Europe and North America. The Group has established a dedicated operation team responsible for this business, and the core members have relevant industry experience.

Smore International (06969): The company's customers include multinational tobacco groups such as Japan Tobacco, British American Tobacco, ReynoldsAsia-Pacific, RELX and NJOY, as well as leading global e-cigarette companies. As a leader in the CBD industry, the company will enjoy industry growth dividends along with the expansion of the marijuana legalization market; in the future, the company will actively develop customers in the medical and health care sector, innovate dosage methods, and use them to treat diseases such as asthma and COPD (chronic obstructive pulmonary disease).